During the past decade, Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 1 clinical trials were completed, i.e. on average, 10% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 1 clinical trials were completed. i.e. 10% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu" #1 collaborator was "Novartis" with 2 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu" are "Dravet Syndrome (DS)" (2 trials), "Lennox Gastaut Syndrome (LGS)" (2 trials), "Migraine" (2 trials), "Chemotherapy-induced Thrombocytopenia" (1 trials) and "Lennox Gastaut Syndrome" (1 trials). Many other conditions were trialed in "Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu" in a lesser frequency.

Most popular intervention types in "Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu" are "Drug" (10 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Soticlestat" (3 trials), "Erenumab Dose 1" (2 trials), "Erenumab Dose 2" (2 trials) and "Erenumab Dose 3" (2 trials). Other intervention names were less common.

The vast majority of trials in "Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu". undefined are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Szpital Kliniczny im. H.Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".